These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8729310)

  • 21. In vitro contracture tests in patients with various neuromuscular diseases.
    Heytens L; Martin JJ; Van de Kelft E; Bossaert LL
    Br J Anaesth; 1992 Jan; 68(1):72-5. PubMed ID: 1739572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man.
    Wappler F; Roewer N; Lenzen C; Köchling A; Scholz J; Steinfath M; Schulte am Esch J
    Br J Anaesth; 1994 Feb; 72(2):240-2. PubMed ID: 8110584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study.
    Metterlein T; Hartung E; Schuster F; Roewer N; Anetseder M
    Minerva Anestesiol; 2011 Aug; 77(8):768-73. PubMed ID: 21730923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility.
    Baur CP; Bellon L; Felleiter P; Fiege M; Fricker R; Glahn K; Heffron JJ; Herrmann-Frank A; Jurkat-Rott K; Klingler W; Lehane M; Ording H; Tegazzin V; Wappler F; Georgieff M; Lehmann-Horn F
    Anesth Analg; 2000 Jan; 90(1):200-5. PubMed ID: 10625004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
    Urwyler A; Censier K; Kaufmann MA; Drewe J
    Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant hyperthermia susceptibility in adult patients with masseter muscle rigidity.
    Allen GC; Rosenberg H
    Can J Anaesth; 1990 Jan; 37(1):31-5. PubMed ID: 2295104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Screening tests for malignant hyperthermia susceptibility].
    Krivosic-Horber R; Adnet P
    Ann Fr Anesth Reanim; 1989; 8(5):444-56. PubMed ID: 2560612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of North American and European malignant hyperthermia group halothane contracture testing protocols in swine.
    Fletcher JE; Conti PA; Rosenberg H
    Acta Anaesthesiol Scand; 1991 Aug; 35(6):483-7. PubMed ID: 1897341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of malignant hyperthermia episodes with the Clinical Grading Scale].
    von Richthofen V; Wappler F; Scholz J; Fiege M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Apr; 33(4):244-9. PubMed ID: 9617423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
    Ording H; Skovgaard LT
    Acta Anaesthesiol Scand; 1987 Jul; 31(5):462-5. PubMed ID: 3630591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New research on muscular function: NMR spectroscopy. Application to malignant hyperthermia].
    Kozak-Reiss G
    Ann Fr Anesth Reanim; 1989; 8(5):400-5. PubMed ID: 2627042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Malignant Hyperthermia - Diagnosis in Practice].
    Girard T; Bandschapp O
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2019 Sep; 54(9):538-548. PubMed ID: 31525787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility.
    Ording H; Islander G; Bendixen D; Ranklev-Twetman E
    Anesth Analg; 2000 Aug; 91(2):452-7. PubMed ID: 10910867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
    Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.